Ann: Opthea Granted Japanese Patent Covering OPT-302, page-7

No particular insights Sol. Opthea is a well run company and runs a very tight ship. It also appears not to be on the radar of most retail biotech investors, which is perhaps not a bad thing. Announcements occur only when there is something of substance to be released. Share price also tightly controlled but good to see something of re-rating in shareprice over January effectively in the absence of news. This is likely to provide a higher base leading into trial results later in year which should see further appreciation in share price as the timeframe to trial announcement outcomes approaches. At the end of the day your guess is as good as mine as to how this year will pan out for Opthea but I am cautiously optimistic. In my opinion there are not too many other Australian biotech that are as well placed, or have the potential of Opthea at this point in time, but of course all this hinges on trial results. Cheers and good luck Yehudi